Navigation Links
Transition in cell type parallels treatment response, disease progression in breast cancer
Date:1/31/2013

A process that normally occurs in developing embryos the changing of one basic cell type into another has also been suspected of playing a role in cancer metastasis. Now a study from Massachusetts General Hospital (MGH) Cancer Center researchers has associated this process, called epithelial-mesenchymal transition or EMT, with disease progression and treatment response in breast cancer patients. The report also identifies underlying mechanisms that someday may become therapeutic targets.

"Until now, EMT had only been modeled in experimental systems, but its clinical relevance was uncertain. Now we show that it can be detected in samples from breast cancer patients and that the tumor cells oscillate between these two states" says Shyamala Maheswaran, PhD, of the MGH Cancer Center, co-corresponding author of the report in the Feb. 1 issue of Science. "We find that the EMT state of breast cancer cells evolves in response to therapy and to disease recurrence, pointing to involvement of this mechanism in tumor spread and invasiveness."

Epithelial tissues line most bodily surfaces and cavities, and epithelial cells closely adhere to each other. During development, some epithelial cells develop traits of mesenchymal cells, including the ability to migrate to other parts of the embryo, establish themselves and develop into organs or other types of tissue. Several studies have suggested that a transition from epithelial to mesenchymal cell type is also involved with cancer metastasis, which involves tumor cells' migration to and invasion of other sites in the body, but identifying EMT stages of tissues has been challenging.

The MGH investigators developed a new assay that determines EMT stage by screening tumor samples for seven epithelial markers and three mesenchymal markers. In primary tumor samples from several breast cancer patients including samples of estrogen-receptor/progesterone-receptor-positive, HER2-positive
'/>"/>

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Topological transitions in metamaterials
2. Study Shows Transition to Practice Programs Get Nurses Employed
3. Innosight Announces Leadership Transition
4. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
5. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
6. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
7. Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response
8. Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union
9. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
10. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
11. MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of ... results for the fourth quarter and full year ended ... Highlights(Compared to the fourth quarter 2013) , Quarterly ... from $22.9 million in the prior year period. Excluding ... vaccine of $0.1 million in the fourth quarter of ...
(Date:4/17/2015)... 17, 2015  Centrillion Technologies, a genomic ... from the National Human Genome Research Institute, ... (NIH). The grant will help fund the ... of breakthrough genomic technologies, including phased sequencing ... Centrillion has been developing this transformative and ...
(Date:4/17/2015)... -- US-Australian drug discovery company, Novogen, today announced that ... the Feinstein Institute for Medical Research (,Feinstein Institute,) ... collaborate with the objective of developing effective treatments ... together the drug discovery expertise of Novogen and ... Institute in neurosciences and oncology. At ...
(Date:4/16/2015)... OSAKA, Japan , April 16, 2015 ... of Kyoto University and Takeda Pharmaceutical Company Limited ... to develop clinical applications of induced pluripotent stem ... mellitus, neurological disorders and cancer immunotherapy. The "Takeda-CiRA ... designed to expedite multiple research projects for drug ...
Breaking Biology Technology:Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3
... are not teaching skills needed for the Information Age. Their ... that we are way beyond the Industrial Age. , ... Rs. I am not talking about reading, writing and `rithmetic; ... these add up to regimentation, which is what was needed ...
... CleanTech Partners will receive $1.5 million from the ... attempt to produce cellulosic ethanol at paper mills by extracting ... paper making. , ,Masood Akhtar, president of CleanTech Partners and ... for the grant. Other participants included the United ...
... Wis. - The origins of Madison's technology industry can ... pretty isolated when he opened DNASTAR, Inc . that year. ... Promega - and a few more, the producer of DNA ... an era where it was considered bad form - even a ...
Cached Biology Technology:Rote education fails the Information Age 2Rote education fails the Information Age 3Rote education fails the Information Age 4DNASTAR catches second wave of sequencing 2DNASTAR catches second wave of sequencing 3DNASTAR catches second wave of sequencing 4
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
(Date:4/2/2015)... According to preliminary estimates Fingerprint ... higher than 125 MSEK. This exceeds the guidance provided ... revenues for Q1 2015 would be in line with ... 2014. The operating result for the first quarter is ... report will as previously communicated be published on May ...
(Date:4/1/2015)... Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces the ... wallets is underway to early access pre-order customers. ... usage at retail outlets including Walmart, Target, AT&T, Dunkin, ... Wocket was accepted at all outlets and very easy ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... in which babies are born can have a dramatic ... That is the conclusion of a new study published ... Neuroscience . The experiment provides the first evidence for ... conducted by Professor of Biological Sciences Douglas McMahon, graduate ...
... for the first time that exactly how we see our environment ... We are all familiar with the idea that our thoughts ... assume that how we perceive the visual world is usually very ... the area at the back of the brain responsible for processing ...
... reversed by activating stem cells that can repair injury in ... from the Universities of Cambridge and Edinburgh have identified a ... sheaths that protect nerve fibres in the brain. ... can be exploited to make the brain,s own stem cells ...
Cached Biology News:Babies' biological clocks dramatically affected by birth light cycle 2Babies' biological clocks dramatically affected by birth light cycle 3Babies' biological clocks dramatically affected by birth light cycle 4Babies' biological clocks dramatically affected by birth light cycle 5Seeing the world differently 2Study reveals new possibility of reversing damage caused by MS 2
Each 72-well MiniTray is low profile, with lid. Conical well shape, 10 l....
... Clone/PAD: ZMD.283. Immunogen: Fusion protein ... Specific for ASIP/PAR-3 (atypical PKC isotype-specific ... antigen is not related to the ... Human Dog Xenopus (positive controls: Caco-2 ...
For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
Request Info...
Biology Products: